过继T细胞治疗癌症：改造T细胞治疗时代

icartab

Adoptive T-cell therapy for cancer: The era of engineered T cells

Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination. It is however clear that several mechanisms encompassing both central and peripheral tolerance limit antitumor immunity, often resulting into progressive diseases. Adoptive T-cell therapy with either allogeneic or autologous T cells can transfer therapeutic immunity. To date, genetic engineering of T cells appears to be a powerful tool for shaping tumor immunity. In this review, we discuss the most recent achievements in the areas of suicide gene therapy, and TCR-modified T cells and chimeric antigen receptor gene-modified T cells. We provide an overview of current strategies aimed at improving the safety and efficacy of these approaches, with an outlook on prospective developments.

过继T细胞治疗癌症：改造T细胞治疗时代

肿瘤起源于多个遗传因素，解除了控制正常细胞行为的管控稳态机制。免疫系统，是专门用于对抗病原的系统，可以识别转化的细胞，在一些条件下能够导致它们的消除。然而可以明确的是，中枢和外周耐受抗肿瘤免疫的限制，经常会导致一些进展性的疾病。异体或自体移植性过继T细胞治疗可以转移免疫性进行治疗。到目前为止，基因修饰的细胞似乎是一个强大免疫治疗的工具。在这篇综述中，我们讨论自杀基因治疗领域的最新成果，TCR基因修饰的T细胞和嵌合抗原受体基因修饰的T细胞治疗方法。我们提供了一个概述目前策略的综述，旨在提高这些方法的安全性和有效性，以及这些技术的发展前景。

关键词：过继T细胞治疗  嵌合抗原受体  基因修饰  免疫治疗  T细胞  T细胞受体

出自爱康得生物技术